Coronavirus Update: Japan Makes Moves On Vaccine Manufacturing

Aug 11 2020

• By Scrip Team

Listen to this article

Takeda has linked up with COVID-19 vaccine frontrunner Novavax, while Daiichi Sankyo has been selected by Japan’s Ministry of Health, Labour and Welfare as an official participant under the first round of a national government initiative to build production capacity.

Coronavirus map — • Source: Shutterstock

Takeda Pharmaceutical Company Limited. has become the latest company to enter into an alliance with Novavax, Inc. for the clinical development, manufacturing and commercialization of NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, this time in Japan. The vaccine is made using the US firm’s recombinant protein nanoparticle technology and saponin-based Matrix‑M adjuvant.

Under the deal, Novavax will license and transfer manufacturing technologies to enable Takeda to manufacture the vaccine antigen and will...

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain
Aug 22 2024
• By Alaric DeArment
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy
Aug 16 2024
• By Alaric DeArment
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
Jul 04 2024
• By Elizabeth Cairns
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
Stock Watch: Thoroughly Moderna Missteps
Jun 18 2024
• By Andy Smith
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj